Paper Details

  1. Home
  2. Paper Details

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.

Author: , HannaGeorge J, JoshiSamit R, KrystalMark, LatailladeMax, LeeSangil, StockDavid A, ZhouNannan

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fostemsavir, a prodrug of temsavir, demonstrated safety, efficacy, and a dose-response relationship when compared to ritonavir-boosted atazanavir in treatment-experienced, HIV-1-infected subjects in a phase 2b trial.
Paper Details　
Original Abstract of the Article :
Fostemsavir is a prodrug of temsavir, an attachment inhibitor that binds to HIV-1 gp120, blocking viral attachment to host CD4 T-cells. The phase 2b trial AI438011 investigated the safety, efficacy, and dose-response of fostemsavir vs ritonavir-boosted atazanavir (ATV/r) in treatment-experienced, HI...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815643/

データ提供：米国国立医学図書館（NLM）

Fostemsavir: A New Antiviral Weapon in the Fight Against HIV

The fight against HIV has been a long and arduous journey, marked by breakthroughs and challenges. This research examines the efficacy of a new antiviral drug, fostemsavir, a prodrug of temsavir, in treating HIV-1-infected individuals. The study, a phase 2b trial, evaluated the safety and effectiveness of fostemsavir compared to a standard antiviral regimen in patients with treatment-experienced HIV-1 infection. The findings offer insights into the potential of fostemsavir to combat HIV-1 and its resistance to existing treatments.

Fostemsavir: A Promising New Antiviral Agent

The study provides encouraging data on the safety and efficacy of fostemsavir, a novel attachment inhibitor that blocks HIV-1 from attaching to host cells. The research highlights the potential of fostemsavir to provide a new therapeutic option for patients with treatment-experienced HIV-1 infection, particularly those who have developed resistance to existing therapies. The study's results are a testament to the ongoing efforts to develop new and effective antivirals in the fight against HIV.

Fostemsavir: A New Frontier in HIV Treatment

This research is a beacon of hope in the fight against HIV. Fostemsavir's potential to combat HIV-1, even in patients who have developed resistance to existing treatments, offers a glimmer of hope for the future. The study's findings provide a foundation for further research into the efficacy and safety of fostemsavir and its role in addressing the ongoing challenges posed by HIV.

Dr.Camel's Conclusion

The study's findings are encouraging and suggest that fostemsavir could be a valuable addition to the arsenal of HIV treatment options. It represents a significant step forward in the ongoing battle against this complex and challenging virus. The research highlights the ongoing efforts to develop new and effective treatments for HIV and the potential of novel approaches to address the challenges posed by drug resistance.

Date :
  1. Date Completed 2019-02-25
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

29206721

DOI: Digital Object Identifier

PMC5815643

Related Literature

Article Analysis
・Effects of fostemsavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.